Ginseng Vesicle Preparation

Initial review brief for cosmetic R&D and ingredient-sourcing teams

Shaanxi Yisai'er Biotechnology Co., Ltd., China, develops and manufactures this freeze-dried preparation in its own R&D platform. Ecyto Biotech is the manufacturer's overseas business.

Source: Panax ginseng | Fresh main root | Plant-derived. Format: individual vials with trehalose, mannitol and sucrose as excipients; no pure-EV mass percentage is offered.

Reference evidence

Historical sample entry	Reported result
Reference lot	CPB05161RS
Particle concentration by RPS	3.00 x 10^10 particles/mL
Mean detected particle diameter	81 nm
Protein by supplier BCA QC	16.6 micrograms/mL
pH in supplier QC	7.02

Particle reports: 22 May 2026; NanoCoulter RPS / Coulter principle, not NTA. Particle values use the company-confirmed 5 mL analytical reconstitution; BCA and pH are corresponding QC entries. These are reference-sample results, not future-batch acceptance limits, EV purity, potency or finished-formula efficacy.

A focused first evaluation

Select a serum, lotion or cream base for a candidate-specific compatibility screen. Addition below 40 C with gentle mixing and initial pH 5-8 are R&D starting proposals, not validated limits. Reconstitution, dose, storage and acceptance criteria must be agreed for the actual sample before testing.

Documentation and supply status

INCI naming applications have been submitted. Results are expected in late November 2026, subject to review; neither the date nor the outcome is guaranteed. Naming does not establish ingredient safety or destination-market authorization.

A corresponding technical-evaluation TDS and available source records can support initial review. Samples require reviewed safety documentation, actual-batch QA release and accepted storage/transport and import arrangements. Validated shelf life and finished-formula efficacy are not established in this brief.

One simple next step

Reply with 'Ginseng + serum / lotion / cream / other' to runji.yang@ecytobiotech.com. No order is needed to request existing non-confidential information. Customization, MOQ, price and lead time are agreed individually.

Technical basis: ECY-TDS-GS, v0.2, 19 October 2026. Non-clinical formulation evaluation only; not for human administration or therapeutic use.